Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: An international collaborative pilot study

Neuropsychopharmacology

Volumn 38, Issue 3, 2013, Pages 492-503

  D'Souza, Deepak C ^a,b,c   Radhakrishnan, Rajiv ^a,b,d   Perry, Edward ^a,b   Bhakta, Savita ^a,b,d   Singh, Nagendra M ^a,b,d   Yadav, Richa ^a,b   Abi Saab, Danielle ^a,b   Pittman, Brian ^a,c   Chaturvedi, Santosh K ^d   Sharma, Mahendra P ^d   Bell, Morris ^a,b   Andrade, Chittaranjan ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale University School of Medicine   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

cognitive retraining; D serine; glutamate; glycine; NMDA receptors; Schizophrenia

Indexed keywords

DEXTRO SERINE; PLACEBO;

ADULT; AGED; AKATHISIA; ALERTNESS; ARTICLE; ATTENTION; COGNITIVE DEFECT; COGNITIVE THERAPY; COMPUTER AIDED DESIGN; COMPUTERIZED COGNITIVE RETRAINING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; GLOBAL COGNITIVE INDEX; HUMAN; INDIA; INFORMATION PROCESSING; INTELLIGENCE QUOTIENT; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; UNITED STATES; VERBAL WORKING MEMORY; WORKING MEMORY;

ADULT; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COMPUTER-ASSISTED INSTRUCTION; COOPERATIVE BEHAVIOR; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; PILOT PROJECTS; SCHIZOPHRENIA; SERINE; TREATMENT OUTCOME;

EID: 84872486732     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.208     Document Type: Article

References (49)

1. Addington D, Addington J, Schissel B (1990). A depression rating scale for schizophrenics. Schizophr Res 3: 247-251.
2. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS (1994). Dopamine D1 receptor mechanisms in the cognitive perfor-mance of young adult and aged monkeys. Psychopharmacology (Berl) 116: 143-151.
3. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Bell MD, Fiszdon JM, Bryson G (2009). Attention training in schizophrenia: differing responses to similar tasks. J Psychiatr Res 43: 490-496.
5. Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D et al (2010). AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 58: 365-373.
6. Buchanan RW, Freedm, an R, Javitt DC, Abi-Dargham A, Lieberman JA (2007). Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 33: 1120-1130.
7. Chen SH, Thomas JD, Glueckauf RL, Bracy OL (1997). The effectiveness of computer-assisted cognitive rehabilitation for persons with traumatic brain injury. Brain Inj 11: 197-209.
8. Coyle JT, Tsai G (2004). The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174: 32-38.
9. d'Amato T, Bation R, Cochet A, Jalenques I, Galland F, Giraud-Baro E et al (2011). A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Schizophr Research 125: 284-290.
10. D'Souza DC, Singh N, Elander J, Carbuto M, Pittman B, de Haes JU et al (2012). Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: pre-liminary evidence. Neuropsychopharmacology 37: 1036-46.
11. Giustizieri M, Armogida M, Berretta N, Federici M, Piccirilli S, Mercuri NB et al (2008). Differential effect of carbamazepine and oxcarbazepine on excitatory synaptic transmission in rat hippocampus. Synapse 62: 783-789.
12. Gordon M (1986). Microprocessor-based assessment of attention deficit disorders (ADD). Psychopharmacol Bull 22: 288-290.
13. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ''right stuff'? Schizophr Bull 26: 119-136.
14. Gustafson EC, Stevens ER, Wolosker H, Miller RF (2007). Endogenous D-serine contributes to NMDA-receptor-mediated light-evoked responses in the vertebrate retina. J Neurophysiol 98: 122-130.
15. Guy W (1976): (reprinted 1991)) ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Educaiton and Welfare: Washington DC
16. Heinrichs DW, Hanlon TE, Carpenter WT Jr. (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10: 388-398.
17. Heinrichs RW, Zakzanis KK (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsy-chology 12: 426-445.
18. Hodge MA, Siciliano D, Withey P, Moss B, Moore G, Judd G et al (2010). A randomized controlled trial of cognitive remediation in schizophrenia. Schizophr Bulletin 36: 419-427.
19. Homayoun H, Moghaddam B (2010). Group 5 metabotropic glutamate receptors: role in modulating cortical activity and relevance to cognition. Eur J Pharmacol 639: 33-39.
20. Javitt DC (2007). Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate inter-actions. Int Rev Neurobiol 78: 69-108.
21. Javitt DC (2009). Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 12: 468-478.
22. Javitt DC, Duncan L, Balla A, Sershen H (2005). Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 10: 275-287.
23. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF et al (2010). High dose D-serine in the treatment of schizophrenia. Schizophr Res 121: 125-130.
24. Kapur S, Mamo D (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsycho-pharmacol Biol Psychiatry 27: 1081-1090.
25. Kay SR, Opler LA, Lindenmayer JP (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisa-tion. Br J Psychiatry Suppl 7: 59-67.
26. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM et al (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64: 633-647.
27. Keefe RS, Eesley CE, Poe MP (2005). Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 57: 688-691.
28. Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A et al (2008). Efficacy and safety ofdonepezil in patients with schizophrenia or schizoaffective disorder: significant place-bo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33: 1217-1228.
29. Keefe RS, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D et al (2011). Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr Bull 37: 1057-1065.
30. Klingberg S, Wolwer W, Engel C, Wittorf A, Herrlich J, Meisner C et al (2011). Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr Bull 37(Suppl 2): S98-110.
31. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169: 215-233.
32. Kurtz MM, Seltzer JC, Fujimoto M, Shagan DS, Wexler BE (2009). Predictors of change in life skills in schizophrenia after cognitive remediation. Schizophr Res. 107: 267-274.
33. Lee CY, Fu WM, Chen CC, Su MJ, Liou HH (2008). Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 49: 888-897.
34. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334: 1-100.
35. McGurk SR, Mueser KT, Feldman K, Wolfe R, Pascaris A (2007a). Cognitive training for supported employment: 2-3 year out-comes of a randomized controlled trial. Am J Psychiatry 164: 437-441.
36. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT (2007b). A meta-analysis of cognitive remediation in schizo-phrenia. Am J Psychiatry 164: 1791-1802.
37. Ninan I, Jardemark KE, Wang RY (2003). Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48: 66-79.
38. O'Donnell CJ, Rogers BN, Bronk BS, Bryce DK, Coe JW, Cook KK et al (2010). Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3. 2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models. J Med Chem 53: 1222-1237.
39. Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV (2001a). UCSD Performance-Based Skills Assessment: develop-ment of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 27: 235-245.
40. Patterson TL, Lacro J, McKibbin CL, Moscona S, Hughs T, Jeste DV (2002). Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia. J Clin Psychopharmacol 22: 11-19.
41. Patterson TL, Moscona S, McKibbin CL, Davidson K, Jeste DV (2001b). Social skills performance assessment among older patients with schizophrenia. Schizophr Res 48: 351-360.
42. Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG (2010). Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Des 16: 309-322.
43. Rebola N, Srikumar BN, Mulle C (2010). Activity-dependent synaptic plasticity of NMDA receptors. J Physiol 588(Pt 1): 93-99.
44. Silverstein SM, Spaulding WD, Menditto AA, Savitz A, Liberman RP, Berten S et al (2009). Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia. Schizophr Bull 35: 222-232.
45. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
46. Tsang HW, Leung AY, Chung RC, Bell M, Cheung WM (2010). Review on vocational predictors: a systematic review of predic-tors of vocational outcomes among individuals with schizo-phrenia: an update since 1998. Aust NZ JPsychiatry 44: 495-504.
47. Umbricht D (2010). Glycine Transporter Type 1 (GLYT1) Inhibitor RG1678: Positive Results of the Proof-of-Concept Study for the Treatment of Negative Symptoms in Schizophrenia'. 49th Annual Meeting of the American College of Neuropsychophar-macology Miami Beach, Florida.
48. Wykes T (2010). Cognitive remediation therapy needs funding. Nature 468: 165-166.
49. Wykes T, Spaulding WD (2011). Thinking about the future cognitive remediation therapy-what works and could we do better? Schizophr Bull 37(Suppl 2): S80-90.